Drug Delivery to the Lungs 23
5th – 7th December 2012
Wednesday 5th December 2012
11.00
Coffee & Registration
12.00 – 13.30
Networking Buffet Lunch in Exhibition Hall
13.30
Welcome and Opening Remarks:
Gary Pitcairn, Chair, DDL Committee
13.45 - 14.30
The DDL Lecture
Phil Haywood DDL Committee
Bronchodilators – the past, present and future
Malcolm Johnson, Respiratory Science Consultant, GlaxoSmithKline
Research & Development, UK
Session 1: Drug Discovery and Development
Chairs: Janet Maas / Darragh Murnane DDL Committee
14.30 - 15.00
Writers, Readers and Erasers’ – The Chemical Biology of Epigenetics
Professor Ian M Adcock FSB, National Heart & Lung Institute,
Imperial College, London
15.00 - 15.30
Circadian Rhythms and Drug Discovery
Professor Stuart Farrow, Respiratory Therapy Area, GlaxoSmithKline,
Stevenage, UK and Faculty of Academic Health Sciences, University
of Manchester, UK
15.30 – 17.00
Posters, Exhibition & Coffee
GROUP A - MANNED POSTER SESSION
17.00- 17.25
Combining Long acting β2 agonists and M3 antagonists for the treatment of
COPD: An evaluation of the potential mechanisms for achieving maximal
bronchodilation
Dr Mark R. Dowling, Investigator III, Novartis Centre for Respiratory
Research
17.25 – 17.45
Understanding the Particle/Lung Cell Interaction, One Particle at a Time
A.E. Haddrell, School of Chemistry, University of Bristol, Bristol, UK
17.45 – 18.05
Cerivastatin Effectively Reduced Pulmonary Artery Hyperplasia,
Pulmonary Artery Pressure and Right Ventricular Thickening upon Local
Delivery to the Lung in a Model of Pulmonary Arterial Hypertension
Jaipal Singh, Georgia Institute of Technology and St. Joseph’s
Translational Research Institute, USA
18.05 - 18.25
Targeted delivery of antimicrobials to the lung: sheep as a clinically
relevant model to assess the pharmacokinetics of colistin and colistin
methanesulfonate after pulmonary and intravenous administration
TH Nguyen, Monash Institute of Pharmaceutical Sciences, Australia
18.25
Close
18.30 – 20.00
Exhibitor Drinks Reception with Entertainment
sponsored by Vectura Group plc
Thursday 6th December 2012 - AM
08.15
Registration and Coffee and Poster Viewing
08.45
Opening of Conference
08. 45 – 09.15
The Ups and Downs of 2012 - a Year in Review
Dr Steven C. Nichols, OINDP Consultancy
Session 2: New Approaches to Pulmonary and Nasal Drug Delivery
Chairs: Omar Usmani / Gary Pitcairn DDL Committee
09.15 - 09.45
Technical challenges faced when developing an inhaled product targeting
delivery to the small airways
Francesca Schiaretti PhD, R&D-CMC-DP Development Department,
Chiesi Farmaceutici S.p.A., Italy
09.45 - 10.15
Novel imaging in assessing small airway disease and therapy
Dr. Jan De Backer, CEO FluidDA nv, Belgium
10.15 - 10.45
Clinical relevance of small airways directed therapy
Assoc. Professor, M.D., FCCP Arschang Valipour, Ludwig-Boltzmann
Institute for COPD and Respiratory Epidemiology, Austria
10.45 - 11.45
Coffee/Tea Break
GROUP B - MANNED POSTER SESSION
11.45 - 12.05
Does aerosol particle size affect total and peripheral lung deposition in children
with cystic fibrosis?
S G Devadason, School of Paediatrics and Child Health, University of
Western Australia, Australia
12.05 - 12.25
In Vivo/In Vitro Comparison of Aerosol Nasal Deposition
L Vecellio, DTF-Aerodrug, Faculty of medicine, France
12.25 - 12.55
Development of a Nasal Virus-Like-Particle Vaccine Formulation Using
a Spray Dry Process
Dr David T Vodak, Bend Research, Inc., USA
12.55 – 14.30
Lunch
Thursday 6th December – PM
Session 3: Pat Burnell New Investigator Award
Chairs: Omar Usmani, Ben Forbes, Phil Haywood, DDL Committee
Eva Littringer, Research Center Pharmaceutical Engineering GmbH, Austria
14.30 – 14.45
Analysis of pMDI aerosol plume dynamics via laser diffraction using the
Sympatec Helos
F Freestone, Chiesi Ltd, UK
14.45 - 15.00
The Bipolar Next Generation Impactor (bp-NGI) as a Tool for the
Simultaneous Measurement of the Bipolar Charge Distribution and
Mass Quantification of Aerosols for Inhalation
Martin Rowland, Department of Pharmacy and Pharmacology,
University of Bath, UK
15.00 - 15.15
Aerodynamic size-fractionated sub-populations of salmeterol xinafoate
and fluticasone propionate powders possess distinct properties and
aerosolisability
S Jaffari, King’s College London, Institute of Pharmaceutical Sciences, UK
15.15 - 15.30
Absorption Profiling of Inhaled Liposomal Ciprofloxacin Nanoparticles using
Isolated Perfused Lung
Hui Xin Ong, Woolcock Institute of Medical Research, The University of
Sydney, Australia
15.30 - 15.45
Challenges in bronchial challenge testing
A J Lexmond, Department of Pharmaceutical Technology and
Biopharmacy, University of Groningen, The Netherlands
15.45 - 16.50
Coffee/Tea Break
Session 4: Advances In Analytical Science For Respiratory Products
Chairs: Matt Pollard / Mark Hammond, DDL Committee
16.50 - 17.20
Opportunities for Clinically Relevant Methods in the Laboratory
Evaluation of Spacers and Valved Holding Chambers (VHCs)
Jolyon Mitchell, Trudell Medical International, Canada
17.20 - 17.45
Development of the Hydraulic Lung
Dr David Prime, Inhaled Product and Device Technology,
GlaxoSmithKline R&D, Ware, Hertfordshire, UK
17.45 - 18.05
Comparison of 3D Imaging and 1D Deposition Models: At Which Dimension?
I Katz, Medical Gases Group, Air Liquide Santé International, France,
Department of Mechanical Engineering, Lafayette College, USA
18.05 - 18.25
Characterization and Feasibility of the Single Particle Mass Spectrometer
(SPAMS) for the Determination of Aerodynamic Particle Size Distributions
and Chemical Composition of Inhalation Products
B. Morrical, Novartis AG Pharma Development, Switzerland
18.30 - 20.30
DDL23 Cocktail Reception and Award Night
Sponsored by Aptar Pharma & Presspart Manufacturing Limited
Friday 7th December 2012
08.15
Coffee and Poster Viewing
09.00 - 09.30
Evaluating the effects of formulation and device design on in vitro
comparability of dry powder inhalers
Professor Robert Price, University of Bath, UK
Session 5: The inhaled market - where is it going?
Chairs: Phil Haywood/Alan Ferrie, DDL Committee
09.30 - 10.00
An Innovative Route to Inhaled Product Industrialisation: The Monash-GSK
Australia Partnership
Ass. Prof. David A V Morton, Monash Institute of Pharmaceutical Sciences,
Monash University, Australia
10.00 – 10.30
Inhalation Technology – What might the future hold?
Mr Phil Seeney, Drug Delivery – PA Consulting Group, Technology and
Innovation, UK
10.30 – 11.30
Coffee/Tea Break
11.30 – 12.00
Real life’ studies – the way ahead in assessing current and new inhaler
therapies
Professor David Price, Professor of Primary Care Respiratory Medicine,
University of Aberdeen, UK
12.00 – 12.30
Inhalation drug delivery products and emerging markets, a “S.W.O.T”
analysis
Mr David Howlett, PharmaDelivery Solutions Ltd, UK
12.30 – 13.00
57 Varieties: Challenging the Barriers to Consumer Choice
P Greenhalgh, Team Consulting Ltd, UK
13.00
Concluding Remarks and Conference Close
Gary Pitcairn, Chair, DDL Committee
13.15
Close